These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10452615)

  • 1. Drug resistance mutations can effect dimer stability of HIV-1 protease at neutral pH.
    Xie D; Gulnik S; Gustchina E; Yu B; Shao W; Qoronfleh W; Nathan A; Erickson JW
    Protein Sci; 1999 Aug; 8(8):1702-7. PubMed ID: 10452615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant.
    Todd MJ; Luque I; Velázquez-Campoy A; Freire E
    Biochemistry; 2000 Oct; 39(39):11876-83. PubMed ID: 11009599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissociation and association of the HIV-1 protease dimer subunits: equilibria and rates.
    Darke PL; Jordan SP; Hall DL; Zugay JA; Shafer JA; Kuo LC
    Biochemistry; 1994 Jan; 33(1):98-105. PubMed ID: 8286367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S; Ross P; Freire E
    Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
    Ohtaka H; Schön A; Freire E
    Biochemistry; 2003 Nov; 42(46):13659-66. PubMed ID: 14622012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties.
    Mildner AM; Rothrock DJ; Leone JW; Bannow CA; Lull JM; Reardon IM; Sarcich JL; Howe WJ; Tomich CS; Smith CW
    Biochemistry; 1994 Aug; 33(32):9405-13. PubMed ID: 8068616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Domain flexibility in retroviral proteases: structural implications for drug resistant mutations.
    Rose RB; Craik CS; Stroud RM
    Biochemistry; 1998 Feb; 37(8):2607-21. PubMed ID: 9485411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
    Ohtaka H; Velázquez-Campoy A; Xie D; Freire E
    Protein Sci; 2002 Aug; 11(8):1908-16. PubMed ID: 12142445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The structural stability of the HIV-1 protease.
    Todd MJ; Semo N; Freire E
    J Mol Biol; 1998 Oct; 283(2):475-88. PubMed ID: 9769219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency.
    Klabe RM; Bacheler LT; Ala PJ; Erickson-Viitanen S; Meek JL
    Biochemistry; 1998 Jun; 37(24):8735-42. PubMed ID: 9628735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. X-ray crystal structures of human immunodeficiency virus type 1 protease mutants complexed with atazanavir.
    Klei HE; Kish K; Lin PF; Guo Q; Friborg J; Rose RE; Zhang Y; Goldfarb V; Langley DR; Wittekind M; Sheriff S
    J Virol; 2007 Sep; 81(17):9525-35. PubMed ID: 17537865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
    Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of mutations on the dimer stability and the pH optimum of the human foamy virus protease.
    Sperka T; Boross P; Eizert H; Tözsér J; Bagossi P
    Protein Eng Des Sel; 2006 Aug; 19(8):369-75. PubMed ID: 16799151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors.
    Ala PJ; Huston EE; Klabe RM; McCabe DD; Duke JL; Rizzo CJ; Korant BD; DeLoskey RJ; Lam PY; Hodge CN; Chang CH
    Biochemistry; 1997 Feb; 36(7):1573-80. PubMed ID: 9048541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs.
    Perryman AL; Lin JH; McCammon JA
    Protein Sci; 2004 Apr; 13(4):1108-23. PubMed ID: 15044738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
    Hong L; Zhang XC; Hartsuck JA; Tang J
    Protein Sci; 2000 Oct; 9(10):1898-904. PubMed ID: 11106162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease.
    Sayer JM; Liu F; Ishima R; Weber IT; Louis JM
    J Biol Chem; 2008 May; 283(19):13459-70. PubMed ID: 18281688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.
    Hou T; Yu R
    J Med Chem; 2007 Mar; 50(6):1177-88. PubMed ID: 17300185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design.
    Velazquez-Campoy A; Kiso Y; Freire E
    Arch Biochem Biophys; 2001 Jun; 390(2):169-75. PubMed ID: 11396919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformational stability and catalytic activity of HIV-1 protease are both enhanced at high salt concentration.
    Szeltner Z; Polgár L
    J Biol Chem; 1996 Mar; 271(10):5458-63. PubMed ID: 8621402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.